CNS Pharmaceuticals found using ticker (CNSP) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 8 and 7 and has a mean target at 7.5. With the stocks previous close at 1.77 this would imply there is a potential upside of 323.7%. The 50 day moving average now sits at 2.19 and the 200 day MA is 2.01. The company has a market cap of $42m. Find out more information at: http://www.cnspharma.com
CNS Pharmaceuticals, a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals was founded in 2017 and is based in Houston, Texas.